85 days ago
Our in house bien pensant PL appears to have stumbled on forecasts from credible tier 1 brokers for how much revenue Croda (CRDA) will make from sales of the Skinbiotherapeutics (SBTX) product Zenakine. The source of this is, PL says, AI so it may be hogwash but it, perhaps, raises two critical points.
